中文
A condition may be “rare,” but no person should feel invisible.
At JY MedTech, we recognize the resilience of the rare disease community and the importance of continued collaboration across science and healthcare.
Today, we stand with patients, families, advocates, and researchers working to increase awareness and accelerate progress.
April-May 2026: Key News in GLP-1 & Peptide Drugs
May 29 | 1. CSPC enters a $18.5 billion global licensing deal with AstraZeneca for peptide platform (including GLP-1...
0 Comments